PL1654002T5 - Kompozycje do dostarczania środków terapeutycznych do oczu - Google Patents
Kompozycje do dostarczania środków terapeutycznych do oczuInfo
- Publication number
- PL1654002T5 PL1654002T5 PL04780382T PL04780382T PL1654002T5 PL 1654002 T5 PL1654002 T5 PL 1654002T5 PL 04780382 T PL04780382 T PL 04780382T PL 04780382 T PL04780382 T PL 04780382T PL 1654002 T5 PL1654002 T5 PL 1654002T5
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- increase
- component
- therapeutics
- eyes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title 1
- 210000004087 cornea Anatomy 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000005499 meniscus Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49318803P | 2003-08-07 | 2003-08-07 | |
| US49317803P | 2003-08-07 | 2003-08-07 | |
| PCT/US2004/025540 WO2005014046A2 (en) | 2003-08-07 | 2004-08-05 | Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
| EP04780382.0A EP1654002B2 (en) | 2003-08-07 | 2004-08-05 | Compositions for delivery of therapeutics into the eyes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL1654002T3 PL1654002T3 (pl) | 2010-03-31 |
| PL1654002T5 true PL1654002T5 (pl) | 2014-06-30 |
Family
ID=34138742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04780382T PL1654002T5 (pl) | 2003-08-07 | 2004-08-05 | Kompozycje do dostarczania środków terapeutycznych do oczu |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8512717B2 (pl) |
| EP (2) | EP1654002B2 (pl) |
| JP (1) | JP2007501799A (pl) |
| AT (1) | ATE444732T1 (pl) |
| AU (1) | AU2004263149B2 (pl) |
| BR (1) | BRPI0413381A (pl) |
| CA (1) | CA2534484A1 (pl) |
| DE (1) | DE602004023516D1 (pl) |
| DK (1) | DK1654002T4 (pl) |
| ES (2) | ES2332049T5 (pl) |
| PL (1) | PL1654002T5 (pl) |
| WO (1) | WO2005014046A2 (pl) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1173790A2 (en) * | 1999-03-01 | 2002-01-23 | Boston Innovative Optics, Inc. | System and method for increasing the depth of focus of the human eye |
| US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
| US7628810B2 (en) * | 2003-05-28 | 2009-12-08 | Acufocus, Inc. | Mask configured to maintain nutrient transport without producing visible diffraction patterns |
| US20050046794A1 (en) * | 2003-06-17 | 2005-03-03 | Silvestrini Thomas A. | Method and apparatus for aligning a mask with the visual axis of an eye |
| PL1654002T5 (pl) | 2003-08-07 | 2014-06-30 | Allergan Inc | Kompozycje do dostarczania środków terapeutycznych do oczu |
| CA2560559C (en) * | 2004-11-05 | 2013-07-02 | Senju Pharmaceutical Co., Ltd. | Aqueous intraocular penetration-promoting eye drop |
| US7976577B2 (en) * | 2005-04-14 | 2011-07-12 | Acufocus, Inc. | Corneal optic formed of degradation resistant polymer |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| WO2007047242A2 (en) * | 2005-10-14 | 2007-04-26 | Soll David B | Ophthalmic surgical irrigating solutions containing hyaluronidase |
| EP1978926A2 (en) * | 2005-12-19 | 2008-10-15 | Comentis, Inc. | Topical mecamylamine formulations for ocular administration and uses thereof |
| US20080107713A1 (en) * | 2006-11-08 | 2008-05-08 | Orilla Werhner C | Contact lens as a sustained drug delivery implant |
| US20080317819A1 (en) * | 2007-06-21 | 2008-12-25 | Orilla Werhner C | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas |
| MX2010003364A (es) | 2007-10-08 | 2010-07-06 | Lux Biosciences Inc | Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor. |
| US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
| US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
| TW201039815A (en) | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
| WO2010144194A1 (en) * | 2009-06-09 | 2010-12-16 | Lux Biosciences, Inc. | Topical drug delivery systems for ophthalmic use |
| CN102448404B (zh) | 2009-08-13 | 2015-06-10 | 阿库福库斯公司 | 掩盖型眼内植入物和透镜 |
| USD656526S1 (en) | 2009-11-10 | 2012-03-27 | Acufocus, Inc. | Ocular mask |
| BR112012013503B8 (pt) | 2009-12-03 | 2021-05-25 | Alcon Res Llc | composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade |
| RU2452478C1 (ru) * | 2011-02-21 | 2012-06-10 | Общество с ограниченной ответственностью "Научно-производственная компания Уралбиофарм" | Многофункциональный раствор для эпибульбарных инстилляций |
| KR102042290B1 (ko) | 2011-11-21 | 2019-11-07 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 글루타미나제의 헤테로사이클릭 억제제 |
| JP6046160B2 (ja) | 2011-12-02 | 2016-12-14 | アキュフォーカス・インコーポレーテッド | 選択的分光透過性を有する眼科マスク |
| EP2690605B1 (en) | 2012-07-24 | 2015-04-29 | Scan Coin Ab | Dispensers for coin handling apparatus |
| EP2690604B1 (en) | 2012-07-24 | 2021-05-26 | Scan Coin Ab | Coin deposit and dispensing apparatus |
| EP2690607B1 (en) | 2012-07-24 | 2024-03-27 | Scan Coin Ab | Apparatus, method and computer program for flexible dispensing of coins in a coin handling apparatus |
| KR102124667B1 (ko) | 2012-07-26 | 2020-06-18 | 알레간 인코포레이티드 | 쉘프 저장 동안 팁 무균상태를 유지하기 위한 용기-마개들용 이중 캡 시스템 |
| EA029707B1 (ru) | 2012-11-16 | 2018-05-31 | Калитера Байосайенсиз, Инк. | Гетероциклические ингибиторы глютаминазы |
| US9204962B2 (en) | 2013-03-13 | 2015-12-08 | Acufocus, Inc. | In situ adjustable optical mask |
| US9427922B2 (en) | 2013-03-14 | 2016-08-30 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| WO2015094392A1 (en) * | 2013-12-18 | 2015-06-25 | Gnt, Llc | Compositions and methods for treatment of glaucoma |
| KR20170012562A (ko) | 2014-06-13 | 2017-02-02 | 칼리테라 바이오사이언시즈 인코포레이티드 | 글루타미나제 억제제를 사용하는 병용 요법 |
| CN106999490A (zh) | 2014-08-07 | 2017-08-01 | 卡利泰拉生物科技公司 | 晶体形式的谷氨酰胺酶抑制剂 |
| WO2016025669A1 (en) | 2014-08-13 | 2016-02-18 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
| RS62960B1 (sr) | 2015-03-10 | 2022-03-31 | Aurigene Discovery Tech Ltd | Jedinjenja 1,2,4-oksadiazola i tiadiazola kao imunomodulatori |
| WO2016210106A1 (en) | 2015-06-23 | 2016-12-29 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| WO2017062354A1 (en) | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| SG11201802961PA (en) | 2015-10-30 | 2018-05-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| JP7019585B2 (ja) | 2015-11-16 | 2022-02-15 | アヴァロ セラピューティクス，インコーポレーテッド | 核酸プロドラッグ |
| BR112018016446B1 (pt) | 2016-02-12 | 2024-02-06 | Eolas Therapeutics, Inc. | Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos |
| WO2017210565A1 (en) | 2016-06-03 | 2017-12-07 | Prisident And Fellows Of Harvard College | Antifungal compounds |
| WO2018031973A1 (en) | 2016-08-12 | 2018-02-15 | Silk Technologies, Ltd. | Silk-derived protein for treating inflammation |
| MX2019001877A (es) * | 2016-08-19 | 2019-09-13 | Orasis Pharmaceuticals Ltd | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. |
| US11077151B2 (en) | 2016-08-25 | 2021-08-03 | California Institute Of Technology | Ascaroside treatment of autoimmune and inflammatory diseases |
| US11583516B2 (en) | 2016-09-07 | 2023-02-21 | Trustees Of Tufts College | Dash inhibitors, and uses related thereto |
| US10472364B2 (en) | 2016-09-09 | 2019-11-12 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| EP3509583B1 (en) | 2016-09-09 | 2021-06-30 | The Regents of the University of California | Estrogen receptor ligands, compositions and methods related thereto |
| BR112019004992A2 (pt) | 2016-09-14 | 2019-06-04 | Univ Vanderbilt | inibição da sinalização de bmp, compostos, composições e usos destes |
| EP4275759A3 (en) | 2016-09-26 | 2024-01-17 | Dana-Farber Cancer Institute, Inc. | Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer |
| EP3538111B1 (en) | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| LT3548091T (lt) | 2016-11-29 | 2022-02-10 | Oculis SA | Kietųjų ciklodekstrino kompleksų paruošimas oftalminių aktyviųjų farmacinių ingredientų vartojimui |
| PT3559009T (pt) | 2016-12-22 | 2021-05-04 | Calithera Biosciences Inc | Composições e métodos para inibir a atividade da arginase |
| US20200054643A1 (en) | 2017-01-18 | 2020-02-20 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| KR20190120786A (ko) | 2017-02-24 | 2019-10-24 | 메르크 파텐트 게엠베하 | 디히드로오로테이트 옥시게나제 억제제로서의 1,4,6-삼치환된-2-알킬-1H-벤조[d]이미다졸 유도체 |
| WO2018209288A1 (en) | 2017-05-12 | 2018-11-15 | Massachusetts Institute Of Technology | Argonaute protein-double stranded rna complexes and uses related thereto |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| WO2018223032A1 (en) | 2017-06-02 | 2018-12-06 | Stealth Biotherapeutics Corp. | Crystalline salt forms of sbt-20 |
| US10526334B2 (en) | 2017-07-19 | 2020-01-07 | California Institute Of Technology | Methods for preparing bis-tetrahydroisoquinoline-containing compounds |
| WO2019070943A1 (en) | 2017-10-04 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE INHIBITION OF SALL4 TRANSCRIPTION FACTOR AND USES THEREOF |
| BR112020006669A2 (pt) | 2017-10-11 | 2020-09-24 | Aurigene Discovery Technologies Limited | formas cristalinas de 1,2,4-oxadiazol 3-substituído |
| SG11202003625VA (en) | 2017-11-03 | 2020-05-28 | Aurigene Discovery Tech Ltd | Dual inhibitors of tim-3 and pd-1 pathways |
| KR20200084333A (ko) | 2017-11-06 | 2020-07-10 | 오리진 디스커버리 테크놀로지스 리미티드 | 면역조절을 위한 병행 요법 |
| KR20200104335A (ko) | 2017-12-22 | 2020-09-03 | 메디뮨 리미티드 | Keap1의 BTB 도메인의 소분자 조절제 |
| WO2019178383A1 (en) | 2018-03-14 | 2019-09-19 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| WO2020023917A1 (en) | 2018-07-27 | 2020-01-30 | California Institute Of Technology | Cdk inhibitors and uses thereof |
| KR20210071974A (ko) | 2018-09-05 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 사이토카인 방출 증후군을 치료하는 방법 |
| JP7504880B2 (ja) | 2018-10-26 | 2024-06-24 | ケロス セラピューティクス インコーポレイテッド | Ａｌｋ２阻害剤の結晶形 |
| CN112930350A (zh) | 2018-10-31 | 2021-06-08 | 尹图赛利有限公司 | 稠合杂环苯并二氮杂䓬衍生物及其用途 |
| KR20210113610A (ko) | 2018-12-10 | 2021-09-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 에스테르 및 이의 용도 |
| LT3911648T (lt) | 2019-01-18 | 2025-01-10 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-onas kaip pcsk9 inhibitorius ir jo naudojimo būdai |
| US20220175749A1 (en) | 2019-03-14 | 2022-06-09 | Astrazeneca Ab | Lanabecestat for weight loss |
| WO2020246503A1 (ja) | 2019-06-03 | 2020-12-10 | 株式会社大分大学先端医学研究所 | 狂犬病治療のための環状アミド化合物およびその方法 |
| CN114040766A (zh) | 2019-07-01 | 2022-02-11 | 奥库里斯公司 | 用于稳定包含药物的水性组合物pH的方法 |
| BR112022009202A2 (pt) | 2019-11-12 | 2022-09-06 | Genzyme Corp | Heteroarilaminosulfonamidas de 6 membros para tratamento de doenças e condições mediadas por atividade deficiente de cftr |
| WO2021113809A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| WO2021113806A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| KR20210076875A (ko) | 2019-12-16 | 2021-06-24 | 주식회사 스마틴바이오 | 신생혈관형성인자의 억제를 위한 화합물 및 그 용도 |
| EP4146626A4 (en) | 2020-05-05 | 2024-05-29 | Nuvalent, Inc. | CHEMOTHERAPEUTIC AGENTS BASED ON HETEROAROMATIC MACROCYCLIC ETHERS |
| AU2022257621A1 (en) | 2021-04-13 | 2023-11-23 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| EP4396176A1 (en) | 2021-09-03 | 2024-07-10 | Genzyme Corporation | Indole compounds and uses thereof in the treatement of cystic fibrosis |
| IL311038A (en) | 2021-09-03 | 2024-04-01 | Genzyme Corp | Indole compounds and methods of use |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| MX2024003439A (es) | 2021-10-01 | 2024-06-21 | Nuvalent Inc | Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático. |
| EP4504736A1 (en) | 2022-04-07 | 2025-02-12 | Nuvalent, Inc. | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds |
| KR20240171153A (ko) | 2022-04-07 | 2024-12-06 | 뉴베일런트, 아이엔씨. | (19r)-5-클로로-3-에틸-16-플루오로-10,19-디메틸-20-옥사-3,4,10,11,23-펜타아자펜타사이클로[19.3.1.02,6.08,12.013,18]펜타코사-1(24),2(6),4,8,11,13,15,17,21(25),22-데카엔-22-아민을사용한 고형 종양의 치료 방법 |
| TW202423948A (zh) | 2022-08-04 | 2024-06-16 | 日商第一工業製藥股份有限公司 | 環狀胜肽衍生物與其製造方法以及組成物 |
| WO2024036098A1 (en) | 2022-08-12 | 2024-02-15 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether compounds |
| WO2024036097A1 (en) | 2022-08-12 | 2024-02-15 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether compounds and isotopologues thereof |
| WO2024086634A1 (en) | 2022-10-19 | 2024-04-25 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| WO2024233456A1 (en) | 2023-05-05 | 2024-11-14 | The Board Of Regents Of The University Of Oklahoma | Variants of adrenomedullin (am) and adrenomedullin 2/intermedin (am2/imd) and methods of use |
| WO2025042868A1 (en) | 2023-08-23 | 2025-02-27 | The Board Of Regents Of The University Of Oklahoma | Combinations of heteroarotinoids and glycolytic inhibitors for use as cancer treatments |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1781701A (en) | 1928-05-16 | 1930-11-18 | Phillips Morris Godfrey Philip | Machine for removing flags and other adhering leaf from the stalks of tobacco leaves |
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
| US4474787A (en) | 1977-05-04 | 1984-10-02 | Fisons Limited | 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof |
| JPS6056684B2 (ja) * | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
| GB2013084B (en) * | 1978-01-25 | 1982-07-28 | Alcon Lab Inc | Ophthalmic drug dosage |
| US4407792A (en) * | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| GB8500310D0 (en) * | 1985-01-07 | 1985-02-13 | Leo Pharm Prod Ltd | Pharmaceutical preparation |
| US6255299B1 (en) * | 1985-01-07 | 2001-07-03 | Leo Pharmaceutical Products Ltd. | Opthalmic gel composition and method of treating eye infections |
| IL80298A (en) * | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US5110493A (en) * | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
| IL87724A (en) | 1987-09-11 | 1992-01-15 | Syntex Inc | Ophthalmic compositions,their preparation and use |
| US5414011A (en) | 1987-09-11 | 1995-05-09 | Syntex (U.S.A.) Inc. | Preservative system for ophthalmic formulations |
| US6174999B1 (en) * | 1987-09-18 | 2001-01-16 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
| US5017229A (en) * | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
| US5705485A (en) * | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
| US5527893A (en) * | 1987-09-18 | 1996-06-18 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
| US4861514A (en) * | 1988-06-08 | 1989-08-29 | The Drackett Company | Compositions containing chlorine dioxide and their preparation |
| US5281591A (en) * | 1989-05-22 | 1994-01-25 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| DE69029804T2 (de) * | 1989-06-07 | 1997-09-04 | Gail S Bazzano | VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL |
| US5045121A (en) * | 1989-06-21 | 1991-09-03 | Gte Products Corporation | Method for removing carbon from cemented tungsten carbide articles |
| US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
| US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5231096A (en) * | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5215991A (en) * | 1990-01-26 | 1993-06-01 | Allergan, Inc. | Combination of selective alpha-adrenergic agonists and Na+ /H+ ex |
| US5212162A (en) * | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| IT1250691B (it) | 1991-07-22 | 1995-04-21 | Giancarlo Santus | Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac. |
| US5460834A (en) * | 1991-12-13 | 1995-10-24 | Alcon Laboratories, Inc. | Combinations of polymers for use in physiological tear compositions |
| WO1993017664A1 (en) * | 1992-03-02 | 1993-09-16 | Alcon Laboratories, Inc. | Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| AU4560493A (en) * | 1992-07-06 | 1994-01-31 | Hansen Transmissions International Nv | Series of gear units |
| AU666957B2 (en) | 1992-08-28 | 1996-02-29 | Alcon Laboratories, Inc. | Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions |
| US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5382591A (en) | 1992-12-17 | 1995-01-17 | Sepracor Inc. | Antipyretic and analgesic methods using optically pure R-ketorolac |
| US5648074A (en) * | 1993-05-25 | 1997-07-15 | Allergan | Compositions and methods for disinfecting contact lenses and reducing proteinaceous deposit formation |
| WO1995005803A1 (en) * | 1993-08-20 | 1995-03-02 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| EP1285657A3 (en) * | 1993-10-13 | 2003-08-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| CA2134376C (en) * | 1993-12-20 | 2001-10-23 | Haresh G. Bhagat | Combinations of polymers for use in physiological tear compositions |
| US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
| US5558876A (en) * | 1995-03-29 | 1996-09-24 | Alcon Laboratories, Inc. | Topical ophthalmic acidic drug formulations |
| IT1283911B1 (it) * | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5807541A (en) * | 1996-04-22 | 1998-09-15 | Sepracor, Inc. | NSAID/fluoride periodontal compositions and methods |
| US5888493A (en) * | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
| US5858346A (en) * | 1997-05-09 | 1999-01-12 | Allergan | Compositions and methods for enhancing contact lens wearability |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| US6646001B2 (en) * | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| WO2000054762A2 (en) * | 1999-03-15 | 2000-09-21 | Trustees Of Boston University | Use of cross linked polysaccharides for the inhibition of angiogenesis |
| ITMI991453A1 (it) | 1999-07-01 | 2001-01-01 | Farmila Farma Milano | Composizioni oftalmiche in forma di gel acquosi |
| US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
| JP4132599B2 (ja) * | 2000-07-07 | 2008-08-13 | 日本板硝子株式会社 | 画像形成装置 |
| JP4927298B2 (ja) * | 2000-07-14 | 2012-05-09 | アラーガン、インコーポレイテッド | α−２−アドレナリンアゴニスト成分を含有する組成物 |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US20020198210A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Alpha-2-adrenergic agonist/fatty acid compositions |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| US7045121B2 (en) * | 2001-12-14 | 2006-05-16 | Allergan, Inc. | Ophthalmic compositions for lubricating eyes and methods for making and using same |
| US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
| US20040224010A1 (en) | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
| US8008338B2 (en) * | 2003-06-03 | 2011-08-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
| TWI336257B (en) | 2003-06-13 | 2011-01-21 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
| PL1654002T5 (pl) | 2003-08-07 | 2014-06-30 | Allergan Inc | Kompozycje do dostarczania środków terapeutycznych do oczu |
| WO2005101982A2 (en) | 2004-03-24 | 2005-11-03 | Sun Pharmaceutical Industries Limited | A stable ophthalmic composition |
| NZ555247A (en) | 2004-12-23 | 2010-06-25 | Roxro Pharma Inc | Therapeutic compositions for intranasal administration of ketorolac |
| AU2007208054A1 (en) * | 2006-01-25 | 2007-08-02 | Aciex Therapeutics, Inc. | Formulations and methods for treating dry eye |
| US20070299124A1 (en) * | 2006-01-25 | 2007-12-27 | Ousler George W Iii | Formulations and methods for treating dry eye |
| US20090010850A1 (en) * | 2007-05-24 | 2009-01-08 | Ousler Iii George W | Formulations and methods for treating dry eye |
| US20080039398A1 (en) * | 2006-01-25 | 2008-02-14 | Ousler George W Iii | Formulations and methods for treating dry eye |
| US20070287741A1 (en) * | 2006-06-13 | 2007-12-13 | Uri Herzberg | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals |
| US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
| CN102076681A (zh) | 2008-04-24 | 2011-05-25 | 阿勒根公司 | 作为治疗剂的取代γ-内酰胺 |
| US20080275118A1 (en) | 2008-06-12 | 2008-11-06 | Shaw Mari M | Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss |
-
2004
- 2004-08-05 PL PL04780382T patent/PL1654002T5/pl unknown
- 2004-08-05 US US10/911,966 patent/US8512717B2/en active Active
- 2004-08-05 JP JP2006522767A patent/JP2007501799A/ja active Pending
- 2004-08-05 WO PCT/US2004/025540 patent/WO2005014046A2/en active Application Filing
- 2004-08-05 DK DK04780382.0T patent/DK1654002T4/da active
- 2004-08-05 BR BRPI0413381-1A patent/BRPI0413381A/pt not_active Application Discontinuation
- 2004-08-05 ES ES04780382.0T patent/ES2332049T5/es not_active Expired - Lifetime
- 2004-08-05 DE DE602004023516T patent/DE602004023516D1/de not_active Expired - Lifetime
- 2004-08-05 AU AU2004263149A patent/AU2004263149B2/en not_active Expired
- 2004-08-05 EP EP04780382.0A patent/EP1654002B2/en not_active Expired - Lifetime
- 2004-08-05 AT AT04780382T patent/ATE444732T1/de active
- 2004-08-05 CA CA002534484A patent/CA2534484A1/en not_active Abandoned
- 2004-08-05 EP EP09010226.0A patent/EP2113246B1/en not_active Expired - Lifetime
- 2004-08-05 ES ES09010226.0T patent/ES2593113T3/es not_active Expired - Lifetime
-
2013
- 2013-07-02 US US13/933,807 patent/US8992952B2/en not_active Expired - Lifetime
-
2015
- 2015-02-24 US US14/629,652 patent/US20150164863A1/en not_active Abandoned
-
2020
- 2020-12-23 US US17/132,246 patent/US20210251961A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1654002B1 (en) | 2009-10-07 |
| EP1654002B2 (en) | 2014-01-29 |
| US20130296396A1 (en) | 2013-11-07 |
| CA2534484A1 (en) | 2005-02-17 |
| EP1654002A2 (en) | 2006-05-10 |
| JP2007501799A (ja) | 2007-02-01 |
| AU2004263149B2 (en) | 2010-08-19 |
| ATE444732T1 (de) | 2009-10-15 |
| PL1654002T3 (pl) | 2010-03-31 |
| US8992952B2 (en) | 2015-03-31 |
| US20210251961A1 (en) | 2021-08-19 |
| WO2005014046A2 (en) | 2005-02-17 |
| AU2004263149A1 (en) | 2005-02-17 |
| DK1654002T3 (da) | 2010-02-01 |
| US20050031697A1 (en) | 2005-02-10 |
| US20150164863A1 (en) | 2015-06-18 |
| BRPI0413381A (pt) | 2006-10-17 |
| US8512717B2 (en) | 2013-08-20 |
| ES2593113T3 (es) | 2016-12-05 |
| EP2113246A1 (en) | 2009-11-04 |
| DE602004023516D1 (de) | 2009-11-19 |
| DK1654002T4 (da) | 2014-02-17 |
| WO2005014046A3 (en) | 2006-06-01 |
| ES2332049T5 (es) | 2014-03-27 |
| EP2113246B1 (en) | 2016-06-22 |
| ES2332049T3 (es) | 2010-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1654002T3 (pl) | Kompozycje do dostarczania środków terapeutycznych do oczu | |
| WO2004008990A3 (en) | Multiple corneal inlays for gradual refractive correction | |
| MX368377B (es) | Combinacion de brimonidina y timolol para uso oftalmico, topico. | |
| AU3056702A (en) | Methods and compositions for treatment of ocular neovascularization and neural injury | |
| MXPA05013290A (es) | Composiciones oftalmicas que contienen una combinacion sinergistica de dos polimeros. | |
| WO2003074076A3 (en) | Periocular drug delivery for diabetic retinopathy | |
| TW200951533A (en) | Rotationally stabilized contact lenses and methods for their design | |
| WO2005002520A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| TW200626188A (en) | Biomedical devices containing amphiphilic block copolymers | |
| WO2006105403A3 (en) | Treatment of eye disorders with sirtuin modulators | |
| WO2006071548A3 (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases | |
| IL169287A (en) | Sterile ophthalmic formulation, an ocular insert for delivery of same and the use of the formulation | |
| WO2006127987A3 (en) | Treatment of eye disorders with sirtuin modulators | |
| MXPA03007590A (es) | Composiciones y metodos para mejorar suministro de droga a traves de y dentro de tejidos oculares. | |
| WO2005062818A3 (en) | Treatment of ophthalmic conditions | |
| WO2005020907A3 (en) | Ocular drug delivery device | |
| TW200501969A (en) | Ophthalmic compositions containing a synergistic combination of three polymers | |
| DK1110554T3 (da) | Medicinal præparater til behandling af öjensygdomme | |
| EP1623722A4 (en) | COMPOSITION FOR OPHTHALMIC USE | |
| WO2004043354A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| WO2006111735A3 (en) | Device for ameliorating symptoms of gait-impaired patient | |
| GB0603205D0 (en) | Eye-guard | |
| EP1482922A4 (en) | AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS | |
| WO2005041870A3 (en) | Composition and method for the treatment of eye disease | |
| MXPA04000980A (es) | Tratamiento de hipertension ocular y glaucoma. |